Guggenheim Raises ArriVent BioPharma Price Target to $30.00
Guggenheim has increased its price target for ArriVent BioPharma, Inc. from $18.00 to $30.00 per share.
Stocks · News reference
ArriVent BioPharma Announces Initial Phase 1 Results for ARR-217 in Gastrointestinal Cancers
ArriVent BioPharma reported encouraging initial Phase 1 clinical trial results for its CDH17-targeting antibody-drug conjugate, ARR-217, in patients with gastrointestinal malignancies.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ArriVent BioPharma, Inc. (AVBP)
Filed: 2026-10-26 AccNo: 0001104659-26-118550 Size: 220 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
ArriVent BioPharma to Present Phase 1 Data for ARR-217 at ESMO Congress 2026
ArriVent BioPharma announced it will present initial safety and efficacy data from its Phase 1 study of the CDH17-targeted antibody-drug conjugate ARR-217 at the European Society for Medical Oncology (ESMO) Congress 2026.